Unexpected cellular players in Rett syndrome pathology

Neurobiology of Disease

Volumn 92, Issue Part A, 2016, Pages 64-71

  Cronk, James C ^a   Derecki, Noel C ^a   Litvak, Vladimir ^b   Kipnis, Jonathan ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL CPG BINDING PROTEIN 2;

ASTROCYTE; CELL FUNCTION; CELL INTERACTION; CELL POPULATION; CELLS BY BODY ANATOMY; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREACTIVITY; MACROPHAGE; MICROGLIA; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN FUNCTION; RETT SYNDROME; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; HUMANS; RETT SYNDROME;

EID: 84929631256     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.05.005     Document Type: Review

References (88)

1. Alvarez-Saavedra, M., et al. Cell-specific expression of wild-type MeCP2 in mouse models of Rett syndrome yields insight about pathogenesis. Hum. Mol. Genet. 16 (2007), 2315–2325.
2. Alvarez-Saavedra, M., et al. Elevated expression of MeCP2 in cardiac and skeletal tissues is detrimental for normal development. Hum. Mol. Genet. 19 (2010), 2177–2190.
3. American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force., Diagnostic and statistical manual of mental disorders: DSM-5. 2013, American Psychiatric Association, Washington, D.C.
4. Amir, R.E., et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23 (1999), 185–188.
5. Asaka, Y., et al. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol. Dis. 21 (2006), 217–227.
6. Ballas, N., et al. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat. Neurosci. 12 (2009), 311–317.
7. Bialas, A.R., Stevens, B., TGF-beta signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat. Neurosci. 16 (2013), 1773–1782.
8. Braun, S., et al. Pharmacological interference with the glucocorticoid system influences symptoms and lifespan in a mouse model of Rett syndrome. Hum. Mol. Genet. 21 (2012), 1673–1680.
9. Buchovecky, C.M., et al. A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat. Genet. 45 (2013), 1013–1020.
10. Chahrour, M., Zoghbi, H.Y., The story of Rett syndrome: from clinic to neurobiology. Neuron 56 (2007), 422–437.
11. Chahrour, M., et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320 (2008), 1224–1229.
12. Chao, H.T., et al. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56 (2007), 58–65.
13. Chao, H.T., et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468 (2010), 263–269.
14. Chen, R.Z., et al. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27 (2001), 327–331.
15. Chen, Y., et al. Creb1-Mecp2-(m)CpG complex transactivates postnatal murine neuronal glucose transporter isoform 3 expression. Endocrinology 154 (2013), 1598–1611.
16. Cobb, B.L., et al. Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjogren's syndrome. Ann. Rheum. Dis. 69 (2010), 1731–1732.
17. Cohen, S., et al. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 72 (2011), 72–85.
18. Cronk, J.C., et al. Methyl-CpG Binding Protein 2 Regulates Microglia and Macrophage Gene Expression in Response to Inflammatory Stimuli. Immunity 42 (2015), 679–691.
19. Cuddapah, V.A., et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J. Med. Genet. 51 (2014), 152–158.
20. Cunningham, C.L., et al. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. J. Neurosci. 33 (2013), 4216–4233.
21. Dandrea, M., et al. MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines. Nucleic Acids Res. 37 (2009), 6681–6690.
22. Davies, L.C., et al. Tissue-resident macrophages. Nat. Immunol. 14 (2013), 986–995.
23. De Felice, C., et al. Inflammatory lung disease in Rett syndrome. Mediat. Inflamm., 2014, 2014, 560120.
24. Derecki, N.C., et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484 (2012), 105–109.
25. Friez, M.J., et al. Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics 118 (2006), e1687–e1695.
26. Ghisletti, S., et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 23 (2009), 681–693.
27. Giacometti, E., et al. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 1931–1936.
28. Glaze, D.G., Neurophysiology of Rett syndrome. J. Child Neurol. 20 (2005), 740–746.
29. Gold, W.A., et al. Mitochondrial dysfunction in the skeletal muscle of a mouse model of Rett syndrome (RTT): implications for the disease phenotype. Mitochondrion 15 (2014), 10–17.
30. Goldmann, T., et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat. Neurosci. 16 (2013), 1618–1626.
31. Guy, J., et al. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27 (2001), 322–326.
32. Guy, J., et al. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315 (2007), 1143–1147.
33. Guy, J., et al. The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 27 (2011), 631–652.
34. Hagberg, B., et al. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann. Neurol. 14 (1983), 471–479.
35. Haim, Y.O., et al. Resistance of LPS-activated bone marrow derived macrophages to apoptosis mediated by dexamethasone. Sci. Rep., 4, 2014, 4323.
36. Hsiao, E.Y., et al. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 12776–12781.
37. Itoh, M., et al. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains. J. Neuropathol. Exp. Neurol. 66 (2007), 117–123.
38. Jiang, S., et al. MeCP2 reinforces STAT3 signaling and the generation of effector CD4 + T cells by promoting miR-124-mediated suppression of SOCS5. Sci. Signal., 7, 2014, ra25.
39. Jin, L.W., et al. Dysregulation of glutamine transporter SNAT1 in Rett syndrome microglia: a mechanism for mitochondrial dysfunction and neurotoxicity. J. Neurosci. 35 (2015), 2516–2529.
40. Jones, P.L., et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19 (1998), 187–191.
41. Kaufman, K.M., et al. Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann. Rheum. Dis. 72 (2013), 437–444.
42. Kishi, N., Macklis, J.D., MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol. Cell. Neurosci. 27 (2004), 306–321.
43. Koelsch, K.A., et al. Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. J. Autoimmun. 41 (2013), 168–174.
44. Lepelletier, Y., et al. Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood 116 (2010), 3389–3397.
45. Lerner, M.R., Steitz, J.A., Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 76 (1979), 5495–5499.
46. Li, C., et al. MeCP2 enforces Foxp3 expression to promote regulatory T cells' resilience to inflammation. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E2807–E2816.
47. Lioy, D.T., et al. A role for glia in the progression of Rett's syndrome. Nature 475 (2011), 497–500.
48. Litvak, V., et al. A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature 490 (2012), 421–425.
49. Luikenhuis, S., et al. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 6033–6038.
50. Lyst, M.J., et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 16 (2013), 898–902.
51. Maezawa, I., Jin, L.W., Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J. Neurosci. 30 (2010), 5346–5356.
52. Maezawa, I., et al. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J. Neurosci. 29 (2009), 5051–5061.
53. Marchetto, M.C., et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143 (2010), 527–539.
54. McGraw, C.M., et al. Adult neural function requires MeCP2. Science, 333, 2011, 186.
55. Meehan, R.R., et al. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20 (1992), 5085–5092.
56. Mellen, M., et al. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151 (2012), 1417–1430.
57. Moretti, P., et al. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J. Neurosci. 26 (2006), 319–327.
58. Motil, K.J., et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J. Pediatr. Gastroenterol. Nutr. 55 (2012), 292–298.
59. Motil, K.J., et al. Low bone mineral mass is associated with decreased bone formation and diet in girls with Rett syndrome. J. Pediatr. Gastroenterol. Nutr. 59 (2014), 386–392.
60. Nan, X., et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393 (1998), 386–389.
61. Neul, J.L., et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 68 (2010), 944–950.
62. Neul, J.L., et al. Developmental delay in Rett syndrome: data from the natural history study. J. Neurodev. Disord., 6, 2014, 20.
63. Nguyen, M.V., et al. Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology. J. Neurosci. 33 (2013), 18764–18774.
64. Nuber, U.A., et al. Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum. Mol. Genet. 14 (2005), 2247–2256.
65. O'Driscoll, C.M., et al. MeCP2 deficiency enhances glutamate release through NF-kappaB signaling in myeloid derived cells. J. Neuroimmunol. 265 (2013), 61–67.
66. Ogawa, S., et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 (2005), 707–721.
67. Okabe, Y., et al. Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of Rett syndrome. PLoS One, 7, 2012, e35354.
68. Paolicelli, R.C., et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333 (2011), 1456–1458.
69. Rett, A., On a unusual brain atrophy syndrome in hyperammonemia in childhood. Wien. Med. Wochenschr. 116 (1966), 723–726.
70. Samaco, R.C., et al. A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum. Mol. Genet. 17 (2008), 1718–1727.
71. Samaco, R.C., et al. Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 21966–21971.
72. Sawalha, A.H., et al. Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS One, 3, 2008, e1727.
73. Schafer, D.P., et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74 (2012), 691–705.
74. Shahbazian, M.D., Grunstein, M., Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem. 76 (2007), 75–100.
75. Shahbazian, M.D., Zoghbi, H.Y., Rett syndrome and MeCP2: linking epigenetics and neuronal function. Am. J. Hum. Genet. 71 (2002), 1259–1272.
76. Skene, P.J., et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 37 (2010), 457–468.
77. Stevens, B., et al. The classical complement cascade mediates CNS synapse elimination. Cell 131 (2007), 1164–1178.
78. Tudor, M., et al. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 15536–15541.
79. Urdinguio, R.G., et al. Mecp2-null mice provide new neuronal targets for Rett syndrome. PLoS One, 3, 2008, e3669.
80. Wang, Y., et al. Dexamethasone and interleukin-1 potently synergize to stimulate the production of granulocyte colony-stimulating factor in differentiated THP-1 cells. Biochem. Biophys. Res. Commun. 239 (1997), 676–680.
81. Webb, R., et al. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum. 60 (2009), 1076–1084.
82. Williams, E.C., et al. Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum. Mol. Genet. 23 (2014), 2968–2980.
83. Yamazaki, S., et al. Glucocorticoid augments lipopolysaccharide-induced activation of the IkappaBzeta-dependent genes encoding the anti-microbial glycoproteins lipocalin 2 and pentraxin 3. J. Biochem. 157:5 (2015), 399–410.
84. Yan, Q., et al. Nuclear factor-kappaB binding motifs specify Toll-like receptor-induced gene repression through an inducible repressosome. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 14140–14145.
85. Yang, T., et al. Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses. Sci. Transl. Med., 4, 2012 (163ra158).
86. Yasui, D.H., et al. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 19416–19421.
87. Yasui, D.H., et al. MeCP2 modulates gene expression pathways in astrocytes. Mol. Autism, 4, 2013, 3.
88. Zhang, J., et al. Microglial CR3 activation triggers long-term synaptic depression in the hippocampus via NADPH oxidase. Neuron 82 (2014), 195–207.